GLPwatch
Polycystic ovary syndrome
Investigational / off-label
Last updated 2026-05-28 15:46 UTCResearch on semaglutide includes evaluations of its safety profile, though no direct studies on polycystic ovary syndrome (PCOS) were provided in the given source.
AI summary of the sources below.
Approved GLP-1 drugs (0)
No GLP-1 drug is FDA-approved for polycystic ovary syndrome in our data. Any research below reflects investigational or off-label study.
Research (50)
- Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.
- Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
- Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
- Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
- Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
- The benefits of GLP-1 drugs beyond obesity.
- Glucagon-like peptide-1 analogues: An overview.
- Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome.
- Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study.
- Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial.
- Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research.
- A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
- Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.
- Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity.
- Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.
- Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
- Glucagon-like peptide agonists: A prospective review.
- Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.
- Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.
- Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.
- The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls.
- Glucagon-Like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes.
- Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
- Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome.
- GLP-1 receptor agonists in the treatment of polycystic ovary syndrome.
- GLP-1 agonists: A review for emergency clinicians.
- GLP-1 and Its Analogs: Does Sex Matter?
- A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.
- Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies.
- Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
Common questions
- Which GLP-1 drugs are FDA-approved for Polycystic ovary syndrome?
- No GLP-1 drug is currently FDA-approved for polycystic ovary syndrome; any use would be off-label or investigational.
- Is there research on GLP-1 drugs for Polycystic ovary syndrome?
- GLPwatch tracks 147 research papers on GLP-1 drugs and polycystic ovary syndrome. This research is investigational and does not imply FDA approval.